# EGCG for Hepatocellular Carcinoma Chemoprevention

> **NCT06015022** · PHASE2 · RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 60 (estimated)

## Conditions studied

- Cirrhosis, Liver

## Interventions

- **DRUG:** Epigallocatechin gallate (EGCG)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06015022
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2028-08-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06015022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06015022, "EGCG for Hepatocellular Carcinoma Chemoprevention". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06015022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*